Formulation Development and Analysis https://pubs.vensel.org/index.php/fda <p>FDA is an online peer-reviewed journal publishing research articles in the area of Pharmaceutics and Pharmaceutical Analysis.</p> en-US <span>Authors retain copyright and grant the journal right of first publication with the work <span>simultaneously licensed under a </span><a href="http://creativecommons.org/licenses/by/3.0/" target="_new">Creative Commons Attribution License</a><span> that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</span></span> editor.fda@vensel.org (Selvakumar Duraipandi) editor.jphchem@vensel.org (Venkatesan Jayaprakash) Thu, 05 Nov 2015 16:42:17 +0000 OJS 3.3.0.10 http://blogs.law.harvard.edu/tech/rss 60 Pharmacokinetic and Pharmacodynamic interaction between Simvastatin and Diltiazem in rats with induced hypercholesterolaemia and hypertension https://pubs.vensel.org/index.php/fda/article/view/43 <p>3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are often prescribed along with antihypertensive agents, including calcium antagonists. Simvastatin is an HMG-CoA reductase inhibitor and Diltiazem which calcium antagonist it is metabolized by the cytochrome P450 (CYP) 3A4. The purpose of this study is to investigate drug interactions between simvastatin and diltiazem<strong>. </strong>In the present investigation, we studied the pharmacokinetics and dynamics of Simvastatin (SIMVA) alone and in combination with Diltiazem (DILT) in hyperlipidemic and hypertensive rats. The standard cholesterol diet was used to induce hyperlipidemia and 10% fructose solution was used to induce hypertension in Wistar rats. The selected drugs were given for 2 weeks by oral route, simvastatin (2 mg/day), followed by 2 weeks of oral diltiazem (15 mg/day) co-administered with simvastatin (2 mg/day). Combined treatment with simvastatin and diltiazem increased the peak concentration (Cmax) of HMG-CoA reductase inhibitors from 15.64 ± 0.29 µg/mL to 19.45 ± 0.07 (P &lt; 0.01) and the area under the concentration-time curve (AUC) from 60.19 ± 2.24 µg h/mL to 78.4± 0.80 µg h/mL (P &lt; 0.01) without affecting the cholesterol-lowering effect of simvastatin. In hyperlipidemic rats, SIMVA caused a marked reduction in the lipid profiles but combination with DILT produced a significant change. In pharmacokinetics, witnessed insignificant change in the combination of SIMVA and DILT when compared with SIMVA alone. From the results synergistic activity of SIMVA with DILT was witnessed.<strong></strong></p> Venkateshwarlu Eggadi, Sharvana Bhava B.S, Pavani Sriram, Shiva Kumar Revoori, Umasankar kulandaivelu, suresh Gaddam Copyright (c) https://pubs.vensel.org/index.php/fda/article/view/43 Thu, 05 Nov 2015 00:00:00 +0000